- Visibility 898 Views
- Downloads 778 Downloads
- Permissions
- DOI 10.18231/j.ijpo.2025.027
-
CrossMark
Assessing the rate of malignancy in Bethesda category III thyroid nodules and its correlation with histopathology
- Author Details:
-
Lakshmi Agarwal *
-
Hitisha Kumawat
-
Kalpit Jain
-
Manmohan Agrawal
Lakshmi Agarwal *
Kalpit Jain
Manmohan Agrawal
Background: Fine-needle aspiration cytology (FNAC) is a key diagnostic tool for evaluating thyroid nodules. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) classifies thyroid nodules into six categories, with Category III (Atypia of Undetermined Significance - AUS) presenting diagnostic challenges due to its variable malignancy risk, reported between 13% and 30%. This study aims to assess the malignancy risk of Bethesda Category III nodules and analyse the role of cytological and radiological features in malignancy prediction.
Materials and Methods: Retrospective study was conducted on 20 patients diagnosed with Bethesda Category III thyroid nodules on FNAC who subsequently underwent surgical resection. FNAC slides were re-evaluated to assess cytomorphological features such as nuclear atypia, chromatin changes, microfollicular patterns, colloid presence, and lymphocytic infiltration. Histopathological findings were correlated with FNAC results to determine malignancy rates. Additionally, sonographic features such as echogenicity, vascularity, and the presence of calcifications were analysed to assess their predictive value for malignancy.
Results: Among the 20 cases, 35% (7/20) were malignant, while 65% (13/20) were benign. The malignant cases included follicular carcinoma (n=4) and the follicular variant of papillary carcinoma (n=3). The benign cases consisted of nodular goiter (n=6), follicular adenoma (n=6), and Hashimoto thyroiditis (n=1). Hypoechogenicity and irregular margins were observed in 5 malignant cases, and one case demonstrated microcalcifications. FNAC features such as nuclear grooves, chromatin pallor, and microfollicular patterns were significantly associated with malignancy.
Conclusion: Malignancy risk of Bethesda Category III thyroid nodules may be higher than traditionally estimated in the present study. A multidisciplinary approach, integrating cytological, radiological, and clinical findings, is crucial for guiding patient management, including repeat FNAC, molecular testing, or surgical intervention. Due to the limited sample size, further large-scale, multicenter studies are warranted to validate these findings and optimize diagnostic strategies.
Keywords: TBSRTC, AUS, FNAC, Histopathology, ROM.
References
- Krane JF, Vanderlaan PA, Faquin WC, Renshaw AA. The atypia of undetermined significance/follicular lesion of undetermined significance: malignant ratio—a proposed performance measure for reporting in The Bethesda System for Thyroid Cytopathology. Cancer Cytopathol. 2012;120(2):111–6.
- Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA. The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2023;33(9):1039–44.
- Iskandar ME, Bonomo G, Avadhani V, Persky M, Lucido D, Wang B, et al. Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III. Surgery. 2015;157(3):510–7.
- Ratour J, Polivka M, Dahan H, Hamzi L, Kania R, Dumuis ML, et al.. Diagnosis of follicular lesions of undetermined significance in fine-needle aspirations of thyroid nodules. J Thyroid Res. 2013:250347.
- Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27(11):1341–6.
- Park JH, Yoon SO, Son EJ, Kim HM, Nahm JH, Hong S. Incidence and malignancy rates of diagnoses in the bethesda system for reporting thyroid aspiration cytology: an institutional experience. Korean J Pathol. 2014;48(2):133–9.
- Rafi M, Kanwal MA, Awais M, Ahmad T, Tayyab M, Naem MS et al. Unveiling the Malignancy Risk of Surgically Treated Bethesda III Thyroid Nodules: A 10-Year Retrospective Study Comparing Fine-Needle Aspiration Cytology (FNAC) and Histopathology. Cureus. 2024;16(12):e75855.
- Resmi PR, Lilly M. Histopathological insights into Bethesda category 3 thyroid nodules diagnosed by FNAC: A retrospective study on correlation of fine-needle aspiration cytology and histopathology of thyroid. Afr J Biomed Res. 2024;27(3):2217–22.
- Alshalaan AM, Elzain WAD, Alfaifi J, Alshahrani J, Al Qahtani MMM, Al Qahtani HAA et al. Prevalence of malignancy in thyroid nodules with AUS cytopathology: A retrospective cross-sectional study. J Family Med Prim Care. 2024;13(9):3822–8.
- Mosca L, Ferraz da Silva LF, Carneiro PC, Chacon DA, Furtado de Araujo-Neto VJ, Furtado de Araujo-Filho VJ et al. Malignancy rates for Bethesda III subcategories in thyroid fine needle aspiration biopsy (FNAB). Clinics (Sao Paulo). 2018;73:e370. Agarwal et al. / Indian Journal of Pathology and Oncology 2025;12(2):121–125 125
- Bayrak BY, Eruyar AT. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology. BMC Endocr Disord. 2020;20(1):48.
- García Pascual L, Surralles ML, Morlius X, Garcia Cano L, González Mínguez C. Prevalence and associated malignancy of Bethesda category III cytologies of thyroid nodules assigned to the "cytological atypia" or "architectural atypia" groups. Endocrinol Diabetes Nutr (Engl Ed). 2018;65(10):577–83.
- Polyzos SA, Kita M, Avramidis A. Thyroid nodules—stepwise diagnosis and management. Hormones (Athens). 2007;6(2):101–9.
- Bayrak BY, Eruyar AT. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology. BMC Endocr Disord. 2020;20(1):48.
- Ho AS, Sarti EE, Jain KS, Wang H, Nixon IJ, Shaha AR, et al. Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS). Thyroid. 2014;24(5):832–9.
- VanderLaan PA, Marqusee E, Krane JF. Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated fna be the preferred initial approach? Am J Clin Pathol. 2011;135(5):770–5.
- Bagıs M, Can N, Sut N, Tastekin E, Genc Erdogan E, Yilmaz Bulbul B et al. A Comprehensive Approach to the Thyroid Bethesda Category III (AUS) in the Transition Zone between 2nd Edition and 3rd Edition of The Bethesda System for Reporting Thyroid Cytopathology: Subcategorization, Nuclear Scoring, and More. Endocr Pathol. 2024;35(1):51–76.